Latest VIR news and sentiment

WINTON GROUP Ltd significantly reduced its stake in Vir Biotechnology Inc. (NASDAQ:VIR) by 58.3% in the second quarter, selling over 214,000 shares. Despite this reduction, institutional ownership remains high at 65.32%, with major investors like BlackRock and ARCH Venture Management increasing their positions. Vir Biotechnology reported strong quarterly earnings, beating analyst estimates with an EPS of $0.47 and revenue of $238.95 million, maintaining a "Moderate Buy" consensus rating among analysts.

Published

13 Sep 2026 09:56

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Legal & General Group Plc has initiated a new position in Vir Biotechnology, Inc. (NASDAQ:VIR), investing $2.76 million to acquire 270,875 shares, representing approximately 0.16% of the company. Institutional investors now own 65.32% of VIR. Despite a recent earnings beat with EPS of $0.47 against estimates of $0.33 and significant revenue growth, Vir Biotechnology remains unprofitable, with analysts projecting a full-year loss of $1.84 per share, and the stock currently holds a consensus "Moderate Buy" rating.

Published

6 Sep 2026 10:23

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology, Inc. (NASDAQ:VIR) has received a "Moderate Buy" consensus rating from eight brokerage firms, with an average 12-month price target of $21.57. The company recently reported strong quarterly earnings, beating EPS estimates by $0.14 and significantly exceeding revenue expectations with a 19582.5% year-over-year increase. Institutional investors hold a substantial 65.32% of the stock, with several firms increasing their stakes.

Published

5 Sep 2026 09:30

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Man Group plc has acquired a new position in Vir Biotechnology, Inc. (NASDAQ:VIR), purchasing 150,688 shares valued at approximately $1.54 million. This move positions institutional investors to collectively own 65.32% of Vir’s stock. Despite the company reporting strong quarterly earnings and revenue that beat estimates, it remains unprofitable with a negative net margin.

Published

3 Sep 2026 18:28

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Corient Private Wealth LP has invested $3.17 million in Vir Biotechnology, Inc. (NASDAQ:VIR) by purchasing 310,548 shares during the second quarter, making it approximately 0.18% of their holdings in the company. Institutional investors collectively own 65.32% of Vir’s stock. The company recently reported strong quarterly earnings, surpassing analyst estimates with revenues of $238.95 million and EPS of $0.47, and analysts currently have a "Moderate Buy" rating with an average price target of $21.57.

Published

2 Sep 2026 14:36

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology (NASDAQ:VIR) recently hit a new 52-week high of $11.74, closing at $10.94, with institutional investors holding a significant portion of its shares. The company surpassed quarterly earnings expectations, reporting $0.47 EPS against an expected $0.33, and revenues of $238.95 million against a forecast of $135.88 million. Despite this, Vir Biotechnology remains unprofitable with a negative net margin of 638.88%, and analysts have a "Moderate Buy" consensus rating with an average price target of $21.57.

Published

2 Sep 2026 14:36

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology Inc. (VIR) has reached a new 52-week high of $11.66, with its stock currently trading at $11.70 and showing an 81% year-to-date return. This surge is attributed to growing investor confidence, the company's strong financial performance including a net income of $80.1 million in Q2 2026, and advancements in its hepatitis D virus treatment programs. H.C. Wainwright has reiterated a Buy rating with a $20.00 price target, anticipating positive clinical trial data in late 2026 and early 2027.

Published

2 Sep 2026 14:36

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology (NASDAQ:VIR) shares increased by 4.8% to $11.46 on Tuesday, despite trading volume being 88% below average. The company has a "Moderate Buy" consensus rating and an average price target of $21.57 from analysts. This positive movement follows Vir Biotechnology exceeding its quarterly earnings expectations, reporting adjusted EPS of $0.47 and revenue of $238.95 million, significantly above forecasts.

Published

1 Sep 2026 19:10

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology, Inc. announced that its President and CEO, Marianne De Backer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. A live webcast of the event will be available on the company's investor relations website. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases and cancer.

Published

31 Aug 2026 21:05

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology is celebrating its 10-year anniversary by releasing a timeline showcasing its scientific progress, company achievements, traditions, and employee contributions. The company recently reported over $1.0 billion in cash and advancing CHD and oncology pipelines in its second-quarter financial results. As part of its anniversary, Vir Biotechnology also hosted a Family Day, inviting relatives and friends to learn about its operations.

Published

28 Aug 2026 01:10

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Shares of Vir Biotechnology (VIR) climbed almost 9% on Tuesday, continuing an upward trend that has seen the stock gain in 11 of the previous 12 sessions. The surge is attributed to stronger-than-expected revenue, a positive swing in net income despite an EPS miss, and upcoming data catalysts from clinical studies. The company's cash and investments exceeding $1 billion have also boosted investor confidence.

Published

25 Aug 2026 20:15

Catalyst

Earnings

Coverage

Direct company

Duplicates

2 consolidated

Vir Biotechnology (NASDAQ:VIR) shares rose 8.1% to $10.71, though trading volume was significantly lower than average. Analysts generally rate the stock as a "Moderate Buy" with an average price target of $20.62, nearly double its current price. Despite beating quarterly earnings and revenue estimates, the company remains unprofitable, with institutional investors owning a substantial 65.32% of the stock.

Published

25 Aug 2026 17:12

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

A former officer of Vir Biotechnology (VIR), Jason V. O'Byrne, plans to sell up to 23,148 shares of common stock, valued at approximately $242,591.04, through Fidelity Brokerage Services LLC. This planned sale is linked to a stock option exercise, with the transaction expected around August 25, 2026, on NASDAQ. O'Byrne has made two previous sales in August 2026, totaling 39,352 shares for over $387,000.

Published

25 Aug 2026 16:12

Catalyst

Market update

Coverage

Direct company

Duplicates

2 consolidated

Shares of Vir Biotechnology (VIR) climbed almost 9% on Tuesday, continuing an upward trend that has seen the stock gain in 11 of the previous 12 sessions. The surge is attributed to stronger-than-expected revenue, a positive swing in net income despite an EPS miss, and upcoming data catalysts from clinical studies. The company's cash and investments exceeding $1 billion have also boosted investor confidence.

Published

25 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

A former officer of Vir Biotechnology (NASDAQ: VIR), Jason V. O'Byrne, plans to sell up to 14,352 shares of common stock with an aggregate market value of $142,124.00, following a stock option exercise on August 24, 2026. This planned sale comes after O'Byrne previously sold 25,000 shares of Vir common stock in the past three months for $245,297.50. The transaction is being made under Rule 144, which outlines conditions for reselling restricted or insider-held shares.

Published

24 Aug 2026 22:13

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

A former officer of Vir Biotechnology, Inc. (NASDAQ: VIR), Jason V. O'Byrne, has filed a Form 144 notice to potentially sell up to 25,000 shares of common stock, valued at approximately $245,297. The sale is planned for August 21, 2026, through Fidelity Brokerage Services LLC, and is connected to a stock option exercise. This regulatory filing indicates an insider's intention to sell shares previously acquired through stock options.

Published

21 Aug 2026 20:10

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology, Inc. (VIR) is experiencing a record nine-day winning streak, with its stock currently trading at $9.84, up 3.69%. This performance marks its highest close since July 10, 2026, and represents a 12.26% increase over the current streak, the longest in its recorded history. The company's stock is also up 63.18% year-to-date and 125.69% from 52 weeks ago.

Published

19 Aug 2026 12:08

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with revenues reaching US$238.95 million and net income of US$80.08 million, replacing a prior net loss. This unexpected financial performance, driven partly by a collaboration with Astellas, alters the investment narrative by easing near-term funding concerns. However, the company still faces risks related to clinical trial outcomes and long-term development costs, which remain crucial factors for its future valuation and stock performance.

Published

18 Aug 2026 21:41

Catalyst

Earnings

Coverage

Direct company

Duplicates

3 consolidated

Vir Biotechnology (VIR) reported a significant swing to quarterly profitability in Q2 2026, with revenue of US$238.95 million and net income of US$80.08 million, replacing previous losses. This shift is largely attributed to a collaboration with Astellas. While improving short-term funding optics, the company still faces risks related to pivotal trial outcomes and development costs, which could impact its long-term financial profile and fair value.

Published

17 Aug 2026 13:41

Catalyst

Earnings

Coverage

Direct company

Duplicates

2 consolidated

StockInvest.us rates Vir Biotechnology, Inc. (VIR) as a "Buy Candidate" with a technical score of 3.46, noting a 1.62% price gain on the last trading day and a 5.51% increase over two weeks. The analysis indicates mostly positive signals, including buy signals from short and long-term Moving Averages and a pivot bottom point. The stock is expected to trade within a wide horizontal trend between $8.77 and $10.61 over the next three months, with potential resistance at $9.54 and support at $9.16.

Published

15 Aug 2026 15:10

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

15 Aug 2026 13:29

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

15 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology announced complete 96-week Phase 2 SOLSTICE trial data for its combination therapy of tobevibart and elebsiran for chronic hepatitis delta virus (HDV) infection. The regimen demonstrated sustained virologic suppression in 100% of participants and improvements in liver function biomarkers, with no new safety signals. These results support the potential of multi-targeted functional cure strategies for HDV, which is the most severe form of chronic viral hepatitis.

Published

14 Aug 2026 01:41

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology (VIR) reported significant financial improvements in Q2 2026, with $1.01 billion in cash and investments and $238.9 million in revenue, driven by a collaboration with Astellas. The company highlighted strong progress in its hepatitis delta program, with promising clinical trial results for elebsiran and tobevibart, and advanced its oncology pipeline, including the VIR-5500 T-cell engager. VIR projects sufficient capital into the second half of 2028 and anticipates key data readouts for its ECLIPSE studies in late 2026 and early 2027.

Published

12 Aug 2026 23:11

Catalyst

Earnings

Coverage

Direct company

Duplicates

3 consolidated

Vir Biotechnology, Inc. director Robert J. More reported internal share transfers totaling 16,000 shares of common stock, executed on August 11, 2026. These transactions involved transferring shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) for no consideration in connection with the vesting of restricted stock unit awards. Following these transfers, More directly holds 40,656 shares and indirectly holds 517,917 shares through APNG 1, while disclaiming beneficial ownership of the indirect holdings except for his pecuniary interest.

Published

12 Aug 2026 19:39

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology's cash reserves exceeded $1 billion in Q2 2026, extending its operational runway into late 2028, primarily due to a strategic collaboration with Astellas. This deal, involving a $240 million upfront payment and a $75 million equity investment, focuses on VIR-5500 for prostate cancer, with pivotal Phase 3 trials anticipated to begin in 2027. The company also reported significant progress in its chronic hepatitis delta program, with Phase 3 enrollment complete and topline data expected soon.

Published

12 Aug 2026 18:41

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology, Inc. (NASDAQ:VIR) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $20.63, significantly higher than its current price of $8.89. The company recently reported strong quarterly earnings, beating revenue and EPS estimates, despite a negative net margin. Insider activity includes a director selling shares, while institutional investors hold a substantial portion of the company's stock.

Published

11 Aug 2026 09:10

Catalyst

Analyst action

Coverage

Direct company

Duplicates

1 consolidated

Published

9 Aug 2026 03:46

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

State Street Corporation, through its investment management subsidiaries, has disclosed a beneficial ownership of 9,964,151 shares of Vir Biotechnology, Inc. common stock, which represents 5.9% of the class as of June 30, 2026. The filing indicates that all voting and dispositive authority is held on a shared basis among its affiliated investment advisers. This disclosure was made via a SCHEDULE 13G form, which is used for passive investment reporting.

Published

8 Aug 2026 12:39

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with US$80.08 million in net income and sharply increased revenue of US$238.95 million. Despite this improvement, the company missed analyst expectations for both earnings and sales. The article discusses how this mixed performance, alongside strategic collaborations like the Astellas partnership, shapes Vir Biotechnology's investment outlook, emphasizing clinical execution and commercialization as key catalysts.

Published

8 Aug 2026 09:10

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated